MINNEAPOLIS, Feb. 12 /PRNewswire/ -- CoAxia™, Inc. of Maple Grove, MN, announced today the completion of enrollment in its SENTIS randomized, controlled, pivotal trial of NeuroFlo™ Perfusion Augmentation Therapy as an acute interventional treatment for ischemic stroke. The Company plans to complete data collection and analysis of results in Q3 of 2010 and, if warranted, submit a PMA to the US FDA.
